In the ToGA trial, patients with HER2-positive gastroesophageal and gastric adenocarcinoma (locally advanced, recurrent, or metastatic) were randomized to receive Trastuzumab plus chemotherapy (5-fluorouracil or capecitabine and cisplatin) q3w for 6 cycles or chemotherapy alone. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.